Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Jiuping Jay Ji"'
Autor:
Judith E. Karp, Alice Chen, Scott H. Kaufmann, Larry M. Karnitz, James G. Herman, Weijie Poh, Michelle A. Rudek, Ismail Ali-Walbi, Marie Pouquet, Robert J. Kinders, Lihua Wang, Jiuping Jay Ji, Douglas E. Gladstone, Amy E. Dezern, Mark J. Levis, Margaret M. Showel, Hetty E. Carraway, Steven D. Gore, B. Douglas Smith, Amanda L. Blackford, Maria R. Baer, Michael A. McDevitt, Keith W. Pratz, Jan H. Beumer, Ivana Gojo
Purpose: In preclinical studies, the PARP inhibitor veliparib enhanced the antileukemic action of temozolomide through potentiation of DNA damage. Accordingly, we conducted a phase 1 study of temozolomide with escalating doses of veliparib in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cfbbbf2dc6fba4a01ab06722dc6afa6
https://doi.org/10.1158/1078-0432.c.6525036.v1
https://doi.org/10.1158/1078-0432.c.6525036.v1
Autor:
Ralph E. Parchment, James H. Doroshow, Joseph E. Tomaszewski, W. Marston Linehan, Donald P. Bottaro, Robert J. Kinders, Thomas D. Pfister, Suzanne Borgel, Yiping Zhang, Jiuping Jay Ji, Sonny A. Khin, Yvonne A. Evrard, Tony Navas, Jennifer Weiner, Melinda G. Hollingshead, Apurva K. Srivastava
Table S1: Summary of analytical characteristics of full-length MET and pMET assays; data collected from assays run with A549, U87, SNU5 and GTL-16 xenograft tumor extracts. Table S2: Measurement of MET and pMET levels in core needle specimens (#1-5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f4275f2dc106338b0968102684ac3aa
https://doi.org/10.1158/1078-0432.22457915
https://doi.org/10.1158/1078-0432.22457915
Autor:
Ralph E. Parchment, James H. Doroshow, Joseph E. Tomaszewski, W. Marston Linehan, Donald P. Bottaro, Robert J. Kinders, Thomas D. Pfister, Suzanne Borgel, Yiping Zhang, Jiuping Jay Ji, Sonny A. Khin, Yvonne A. Evrard, Tony Navas, Jennifer Weiner, Melinda G. Hollingshead, Apurva K. Srivastava
Purpose: Rational development of targeted MET inhibitors for cancer treatment requires a quantitative understanding of target pharmacodynamics, including molecular target engagement, mechanism of action, and duration of effect.Experimental Design: Sa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92cc82bee0797ee2f6ea9a7f0342ca11
https://doi.org/10.1158/1078-0432.c.6523751
https://doi.org/10.1158/1078-0432.c.6523751
Autor:
Judith E. Karp, Alice Chen, Scott H. Kaufmann, Larry M. Karnitz, James G. Herman, Weijie Poh, Michelle A. Rudek, Ismail Ali-Walbi, Marie Pouquet, Robert J. Kinders, Lihua Wang, Jiuping Jay Ji, Douglas E. Gladstone, Amy E. Dezern, Mark J. Levis, Margaret M. Showel, Hetty E. Carraway, Steven D. Gore, B. Douglas Smith, Amanda L. Blackford, Maria R. Baer, Michael A. McDevitt, Keith W. Pratz, Jan H. Beumer, Ivana Gojo
Table S1. Changes in Proportion (%) of γH2AX-Positive Cells in Peripheral Blood upon Veliparib and Veliparib/Temozolomide Treatment Figure S1. FANCD2 monoubiquitination following ex vivo melphalan treatment of patient bone marrow cells Figure S2.Pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8db147330d1cb9958e7cb54266534082
https://doi.org/10.1158/1078-0432.22462206
https://doi.org/10.1158/1078-0432.22462206
Autor:
Ralph E. Parchment, James H. Doroshow, Joseph E. Tomaszewski, W. Marston Linehan, Donald P. Bottaro, Robert J. Kinders, Thomas D. Pfister, Suzanne Borgel, Yiping Zhang, Jiuping Jay Ji, Sonny A. Khin, Yvonne A. Evrard, Tony Navas, Jennifer Weiner, Melinda G. Hollingshead, Apurva K. Srivastava
Figure S1: Specificity of the MET antibodies demonstrated by Western blot analysis. Figure S2: Effect of freeze-thaw cycles and warm vs cold ischemia time on full-length and pMET levels. Figure S3: Inhibition of tumor growth and intratumoral MET phos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::113c03dc6f2ba086a30ec3d69a8cc619
https://doi.org/10.1158/1078-0432.22457912.v1
https://doi.org/10.1158/1078-0432.22457912.v1
Autor:
Yvonne A. Evrard, Sonny Khin, Tony Navas, Ralph E. Parchment, Apurva K. Srivastava, Donald P. Bottaro, Melinda G. Hollingshead, Thomas D. Pfister, W. Marston Linehan, Suzanne Borgel, Jiuping Jay Ji, Jennifer Weiner, Robert J. Kinders, Joseph E. Tomaszewski, Yiping Zhang, James H. Doroshow
Publikováno v:
Clin Cancer Res
Purpose: Rational development of targeted MET inhibitors for cancer treatment requires a quantitative understanding of target pharmacodynamics, including molecular target engagement, mechanism of action, and duration of effect. Experimental Design: S
Autor:
Li Chen, Larry Rubinstein, James H. Doroshow, Naoko Takebe, Abdul Rafeh Naqash, Robert J. Kinders, Biswajit Das, Ralph E. Parchment, Arjun Mittra, Brandon Miller, Deborah Wilsker, Ashley Bruns, Shivaani Kummar, Alice P. Chen, Lamin Juwara, Khanh T. Do, Geraldine O'Sullivan Coyne, Angie B. Dull, Jiuping Jay Ji, Ting-Chia Chang
Publikováno v:
Journal of Clinical Oncology. 38:3624-3624
3624 Background: Adavosertib, a first-in-class Wee1 kinase inhibitor, abrogates G2/M cell cycle arrest causing premature mitosis and DNA replication stress, yielding enhanced DNA damage. Here we report on potential biomarkers of response from tumor g
Autor:
Robert J. Kinders, Maria R. Baer, Steven D. Gore, Douglas E. Gladstone, James G. Herman, Ivana Gojo, Amy E. DeZern, Larry M. Karnitz, Scott H. Kaufmann, Lihua Wang, Hetty E. Carraway, Judith E. Karp, Michelle A. Rudek, Michael A. McDevitt, Margaret M. Showel, Ismail Ali-Walbi, Amanda L. Blackford, Mark J. Levis, Marie Pouquet, Jan H. Beumer, Weijie Poh, B. Douglas Smith, Keith W. Pratz, Jiuping Jay Ji, Alice P. Chen
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 23(3)
Purpose: In preclinical studies, the PARP inhibitor veliparib enhanced the antileukemic action of temozolomide through potentiation of DNA damage. Accordingly, we conducted a phase 1 study of temozolomide with escalating doses of veliparib in patient
Autor:
James H. Doroshow, Asako J. Nakamura, Yong-Wei Zhang, Yves Pommier, Christophe E. Redon, Robert J. Kinders, Jiuping Jay Ji, Ralph E. Parchment, William M. Bonner
Publikováno v:
Clinical Cancer Research. 16:4532-4542
Tumor cells are often deficient in DNA damage response (DDR) pathways, and anticancer therapies are commonly based on genotoxic treatments using radiation and/or drugs that damage DNA directly or interfere with DNA metabolism, leading to the formatio
Autor:
Shivaani Kummar, Sheila A. Prindiville, Ganesh Mugundu, Lyndsay Harris, Mary Flanagan Quinn, Jiuping Jay Ji, Naoko Takebe, Khanh Tu Do, Robert J. Kinders, Richard Piekarz, Deborah Wilsker, Elad Sharon, Alice P. Chen, Ashley Bruns, Larry Rubinstein, Howard Streicher, Lamin Juwara, Geraldine O'Sullivan Coyne, James H. Doroshow
Publikováno v:
Journal of Clinical Oncology. 36:2587-2587
2587Background: Wee1 tyrosine kinase promotes G2 cell cycle arrest following DNA damage via inactivating phosphorylation of cyclin-dependent kinase 1. We are conducting a phase I study of the oral ...